MRK · CCCC 10-KFeb 26 '26
“• a $2.0 million increase in revenue recognized under our former exclusive license and collaboration agreement with Merck upon receipt of notice of termination in September 2025.”
PFE · CCCC 10-KFeb 26 '26
“Under the terms of the Pfizer Agreement, Pfizer will supply elranatamab for use in the Phase 1b trial at no cost, while we will sponsor, conduct and pay the costs of the trial.”
MRK · CDXS 10-KMar 11 '26
“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.”
PFE · CDXS 10-KMar 11 '26
“This increase was partially offset by the non-recurrence of $6.0 million revenue from our licensing agreement with Roche Sequencing Solutions, Inc. ("Roche") entered into in February 2024, and $9.5 million of revenue related to a license agreement with Pfizer Inc. ("Pfizer") entered into in December 2024.”
MRK · PYXS 10-KMar 23 '26
“Under the terms of the agreement, we are responsible for conducting and funding the study, and Merck is supplying pembrolizumab for use in the trial with no cost to us.”
PFE · PYXS 10-KMar 23 '26
“In December 2020, the Company entered into a license agreement (as amended, the "Pfizer License Agreement") with Pfizer Inc. ("Pfizer") for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including MICVO and PYX-203, and products containing the ADC product candidates.”
MRK · AAPG 20-FApr 29 '26
“We have also established collaborations and other relationships with leading biotechnology and pharmaceutical companies around the world, including a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer”
PFE · AAPG 20-FApr 29 '26
“We have also established collaborations and other relationships with leading biotechnology and pharmaceutical companies around the world, including a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer”
MRK · IMMP 20-FOct 24 '25
“In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004. In addition to working together, MSD was also supplying KEYTRUDA at no cost for the trial.”
PFE · IMMP 20-FOct 24 '25
“In November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial. It is the second agreement entered into by Immutep with Merck KGaA and Pfizer”